Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Beth Israel Deaconess Medical Center
NRG Oncology
Lumos Pharma
Actuate Therapeutics Inc.
UNC Lineberger Comprehensive Cancer Center
Arcus Biosciences, Inc.
Bristol-Myers Squibb
iOnctura
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
EBG MedAustron GmbH
Medical College of Wisconsin
Akeso
Lokon Pharma AB
Ohio State University Comprehensive Cancer Center
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Emory University
Queen Mary University of London
Alliance for Clinical Trials in Oncology
Mayo Clinic
Suzhou Transcenta Therapeutics Co., Ltd.
Emory University
Mayo Clinic
University Health Network, Toronto
M.D. Anderson Cancer Center
Jinling Hospital, China
University of Southern California
Thomas Jefferson University
GWT-TUD GmbH
Verastem, Inc.
University of Iowa
City of Hope Medical Center
Emory University
University of Colorado, Denver
AHS Cancer Control Alberta
Columbia University
Lisata Therapeutics, Inc.
SynerGene Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Georgetown University
Precision Biologics, Inc
InxMed (Shanghai) Co., Ltd.
NovoCure Ltd.
Dana-Farber Cancer Institute
Herlev Hospital
Aalborg University Hospital
Shanghai Zhongshan Hospital